Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2022-11-20 AGM Information
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Nyrada AGM 2022 Chairmans Address 4 pages 367.1KB
AGM Information Classification · 95% confidence The document is titled 'Nyrada AGM 2022 Chairman’s Address' and is dated 21 November 2022. It is a speech given by the Chairman at the Annual General Meeting (AGM) of Nyrada Inc. The content includes reflections on the past year's achievements, updates on drug development programs, board changes, and financial positioning, all typical of a chairman's address at an AGM. There is no detailed financial data or comprehensive financial statements present, which would be expected in an Annual Report (10-K) or Interim Report (IR). The document is not a transcript of a call, nor is it an announcement of voting results or a regulatory filing. It is a presentation or speech given at the AGM, which fits the definition of AGM Information (AGM-R). The document length (9761 characters) supports that it is a substantive address rather than a brief announcement. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-11-20 English
AGM Presentation by James Bonnar CEO 26 pages 1.5MB
AGM Information Classification · 100% confidence The document is titled 'Annual General Meeting Presentation' and contains detailed slides with forward-looking statements, business model overview, drug programs, clinical trial designs, and market opportunities. It is clearly a presentation prepared for the Annual General Meeting (AGM) of Nyrada Inc. The content is typical of an AGM presentation, focusing on company strategy, pipeline, and milestones rather than a full annual report or financial statements. There is no indication that this is a full Annual Report (10-K), Earnings Release, or other regulatory filing. The length (15,000 characters) and detailed slide content support it being a presentation rather than a brief announcement or certification. Therefore, the correct classification is AGM Information (AGM-R).
2022-11-20 English
Results of Meeting 4 pages 257.3KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Nyrada Annual General Meeting Results' and dated 21 November 2022. It announces the results of the Annual General Meeting (AGM) including voting outcomes on various resolutions such as re-election of directors and approval of equity incentive plans. The text references compliance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act, which relate to disclosure of voting results. The document contains detailed proxy vote counts and poll results for each resolution. There is no financial data or management discussion, only the official voting results from the AGM. The document length is 5620 characters, which is sufficient to include detailed voting results rather than just a brief announcement. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-20 English
Nyrada Receives A$1.2M R&D Tax Incentive Rebate 2 pages 219.4KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement about Nyrada Inc receiving a cash rebate from the Australian Government's R&D tax incentive program for the 2022 financial year. It does not contain any financial statements, detailed financial performance data, or comprehensive report content. The length is only 3081 characters, which is quite short and typical of a press release or announcement rather than a full report. There is no indication that this is an annual report, interim report, earnings release, or any other detailed financial filing. It is also not a regulatory certification or officer attestation. The content focuses on a specific funding update related to R&D tax incentives, which is a capital/financing update type of information. Therefore, the best fitting category is Capital/Financing Update (CAP).
2022-11-17 English
CEO Remuneration Update 2 pages 198.1KB
Remuneration Information Classification · 95% confidence The document is a company announcement specifically about changes to the CEO's remuneration package, including details of the fixed annual remuneration and a statement from the Chairman. It does not contain financial statements, audit information, or detailed management discussion of financial results. The content focuses solely on executive compensation updates. This matches the definition of Remuneration Information filings, which detail compensation for top executives and directors. The document length is under 5,000 characters and is a direct announcement, not a report or presentation. Therefore, the appropriate classification is DEF 14A (Remuneration Information).
2022-10-26 English
Quarterly Activities Report and Appendix 4C 10 pages 489.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Quarterly Activities Report & Appendix 4C' and includes detailed operational updates on drug development programs, clinical trial progress, and financial summaries including cash flow statements for the quarter ending 30 September 2022. The presence of an Appendix 4C cash flow report, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly report. The document contains substantive financial data and analysis, including cash operating outflows, cash position, and detailed program updates, which are characteristic of an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but a comprehensive quarterly update with financial and operational details. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-10-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.